On March 13, 2025 ChromaDex Corp. (NASDAQ:CDXC), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, reported that it will change its corporate name to Niagen Bioscience, Inc. and trade under the new Nasdaq symbol "NAGE" effective at stock market open on Wednesday, March 19, 2025 (Press release, ChromaDex, MAR 13, 2025, View Source [SID1234651123]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As part of this transition, the Company will deploy a follow-up announcement with additional updates regarding the name change, rebrand, and future initiatives.

No action is required by existing shareholders with respect to the ticker symbol change. The Company’s common stock will continue to be listed on Nasdaq and the CUSIP will remain unchanged.

For additional information on ChromaDex, visit www.chromadex.com.